Schwab M - Search Results

1

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.

Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Lima JJ, et al. Among authors: schwab m. Clin Pharmacol Ther. 2021 Jun;109(6):1417-1423. doi: 10.1002/cpt.2015. Epub 2020 Sep 20. Clin Pharmacol Ther. 2021. PMID: 32770672 Free PMC article.

2

Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.

Lutz M, Schwab M, Griese EU, Marx C, Müller-Oerlinghausen B, Schönhöfer PS, Meisner C, Gleiter CH, Eichelbaum M, Mörike K. Lutz M, et al. Among authors: schwab m. Pharmacogenetics. 2002 Jan;12(1):73-5. doi: 10.1097/00008571-200201000-00010. Pharmacogenetics. 2002. PMID: 11773867

3

Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.

Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM. Richter T, et al. Among authors: schwab m. J Pharmacol Exp Ther. 2004 Jan;308(1):189-97. doi: 10.1124/jpet.103.056127. Epub 2003 Oct 16. J Pharmacol Exp Ther. 2004. PMID: 14563790

4

CYP2C19 polymorphism and proton pump inhibitors.

Klotz U, Schwab M, Treiber G. Klotz U, et al. Among authors: schwab m. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):2-8. doi: 10.1111/j.1600-0773.2004.pto950102.x. Basic Clin Pharmacol Toxicol. 2004. PMID: 15245569 Free article. Review.

5

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.

Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, Schwab M, Zanger UM. Raimundo S, et al. Among authors: schwab m. Clin Pharmacol Ther. 2004 Aug;76(2):128-38. doi: 10.1016/j.clpt.2004.04.009. Clin Pharmacol Ther. 2004. PMID: 15289790

6

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.

Schwab M, Schaeffeler E, Klotz U, Treiber G. Schwab M, et al. Clin Pharmacol Ther. 2004 Sep;76(3):201-9. doi: 10.1016/j.clpt.2004.05.002. Clin Pharmacol Ther. 2004. PMID: 15371981

7

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.

Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G. Schwab M, et al. Clin Pharmacol Ther. 2005 Dec;78(6):627-34. doi: 10.1016/j.clpt.2005.08.017. Clin Pharmacol Ther. 2005. PMID: 16338278 Clinical Trial.

8

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT. Igel M, et al. Among authors: schwab m. Clin Pharmacol Ther. 2006 May;79(5):419-26. doi: 10.1016/j.clpt.2006.01.010. Epub 2006 Apr 11. Clin Pharmacol Ther. 2006. PMID: 16678544 Clinical Trial.

9

Pharmacogenomics of tamoxifen therapy.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Brauch H, et al. Among authors: schwab m. Clin Chem. 2009 Oct;55(10):1770-82. doi: 10.1373/clinchem.2008.121756. Epub 2009 Jul 2. Clin Chem. 2009. PMID: 19574470 Review.

10

Warfarin pharmacogenetics meets clinical use.

Schwab M, Schaeffeler E. Schwab M, et al. Blood. 2011 Sep 15;118(11):2938-9. doi: 10.1182/blood-2011-07-367763. Blood. 2011. PMID: 21921056 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,869 results

Search Page